OperaV1, PascalFrancis, Curation, bibRecord, 000347

Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study

Identifieur interne : 000347 ( PascalFrancis/Curation ); précédent : 000346; suivant : 000348

Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study

Auteurs : Eric Van Belle [France] ; Jean Dallongeville [France] ; Eric Vicaut [France] ; Alexia Degrandsart [France] ; Cathrine Baulac [France] ; Gilles Montalescot [France]

Source :

The American heart journal [ 0002-8703 ] ; 2010.

RBID : Pascal:10-0215806

Descripteurs français

Pascal (Inist)
- Ischémie, Infarctus du myocarde, Pathologie de l'appareil circulatoire, Albumine, Niveau, Facteur prédictif, Long terme, Pronostic, Homme, Malade, Aigu, France, Appareil circulatoire, Cardiologie.
Wicri :
- geographic : France.
- topic : Homme.

English descriptors

KwdEn :
- Acute, Albumin, Cardiology, Cardiovascular disease, Circulatory system, France, Human, Ischemia, Level, Long term, Myocardial infarction, Patient, Predictive factor, Prognosis.

Abstract

Background Little is known about the capacity of ischemia-modified albumin (IMA) plasma concentration to predict long-term cardiac outcome in patients with established acute myocardial infarction (AMI). Because IMA is a marker of ischemia rather than myocardial cell damage, we hypothesized that IMA plasma levels could provide additional prognostic value to classic clinical and biological risk markers in patients with AMI. Therefore, we investigated the predictive value of plasma IMA in patients with AMI enrolled in the French Nationwide OPERA study. Methods Plasma concentrations of IMA and other cardiac biomarkers (troponin, C-reactive protein, B-type natriuretic peptide) were measured within 24 hours of hospital admission in 471 patients hospitalized with an AMI (defined using European Society of Cardiology/American College of Cardiology criteria). Patients' characteristics, cardiovascular risk factors and treatments, and clinical outcomes were recorded. Univariate and multivariable predictors of cardiac outcome in-hospital and at 1 year were identified. Results The primary composite end point (death, resuscitated cardiac arrest, recurrent myocardial infarction or ischemia, heart failure, stroke) occurred in 75 (15.6%) patients in-hospital and in 144 (30.6%) at 1 year: 40% of patients in the highest IMA quartile (>104 IU/mL) reached the end point compared with 20% in the lowest (<83 IU/mL) by 1 year. Multivariable logistic regression analysis identified 4 independent predictors of composite end point at 1 year: plasma concentrations of IMA (P = .01), brain natriuretic peptide (P = .001), heart failure (P = .005), and age (P = .003). Conclusions In patients with AMI, IMA measured within 24 hours is a strong and independent predictor of cardiac outcome at 1 year and may help identify those requiring more aggressive medical management.

A01	`01`	`1`		`@0 0002-8703`
A02	`01`			`@0 AHJOA2`
A03		`1`		`@0 Am. heart j.`
A05				`@2 159`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study`
A11	`01`	`1`		`@1 VAN BELLE (Eric)`
A11	`02`	`1`		`@1 DALLONGEVILLE (Jean)`
A11	`03`	`1`		`@1 VICAUT (Eric)`
A11	`04`	`1`		`@1 DEGRANDSART (Alexia)`
A11	`05`	`1`		`@1 BAULAC (Cathrine)`
A11	`06`	`1`		`@1 MONTALESCOT (Gilles)`
A14	`01`			`@1 Hopital Cardiologique and EA2693 @2 Lille @3 FRA @Z 1 aut.`
A14	`02`			`@1 Institut Pasteur and INSERM U744 @2 Lille @3 FRA @Z 2 aut.`
A14	`03`			`@1 Hopital F. VIDAL @2 Paris @3 FRA @Z 3 aut.`
A14	`04`			`@1 Laboratoires PFIZER @2 Paris @3 FRA @Z 4 aut. @Z 5 aut.`
A14	`05`			`@1 Institut de Cardiologie, Pitié-Salpétrière University Hospital @2 Paris @3 FRA @Z 6 aut.`
A17	`01`	`1`		`@1 OPERA Investigators @3 INC`
A20				`@1 570-576`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2057 @5 354000182014920090`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 10-0215806`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The American heart journal`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background Little is known about the capacity of ischemia-modified albumin (IMA) plasma concentration to predict long-term cardiac outcome in patients with established acute myocardial infarction (AMI). Because IMA is a marker of ischemia rather than myocardial cell damage, we hypothesized that IMA plasma levels could provide additional prognostic value to classic clinical and biological risk markers in patients with AMI. Therefore, we investigated the predictive value of plasma IMA in patients with AMI enrolled in the French Nationwide OPERA study. Methods Plasma concentrations of IMA and other cardiac biomarkers (troponin, C-reactive protein, B-type natriuretic peptide) were measured within 24 hours of hospital admission in 471 patients hospitalized with an AMI (defined using European Society of Cardiology/American College of Cardiology criteria). Patients' characteristics, cardiovascular risk factors and treatments, and clinical outcomes were recorded. Univariate and multivariable predictors of cardiac outcome in-hospital and at 1 year were identified. Results The primary composite end point (death, resuscitated cardiac arrest, recurrent myocardial infarction or ischemia, heart failure, stroke) occurred in 75 (15.6%) patients in-hospital and in 144 (30.6%) at 1 year: 40% of patients in the highest IMA quartile (>104 IU/mL) reached the end point compared with 20% in the lowest (<83 IU/mL) by 1 year. Multivariable logistic regression analysis identified 4 independent predictors of composite end point at 1 year: plasma concentrations of IMA (P = .01), brain natriuretic peptide (P = .001), heart failure (P = .005), and age (P = .003). Conclusions In patients with AMI, IMA measured within 24 hours is a strong and independent predictor of cardiac outcome at 1 year and may help identify those requiring more aggressive medical management.
C02	`01`	`X`		`@0 002B12A03`
C02	`02`	`X`		`@0 002B12A05`
C03	`01`	`X`	`FRE`	`@0 Ischémie @5 01`
C03	`01`	`X`	`ENG`	`@0 Ischemia @5 01`
C03	`01`	`X`	`SPA`	`@0 Isquemia @5 01`
C03	`02`	`X`	`FRE`	`@0 Infarctus du myocarde @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Myocardial infarction @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Infarto miocardio @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 03`
C03	`03`	`X`	`ENG`	`@0 Cardiovascular disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Albumine @5 09`
C03	`04`	`X`	`ENG`	`@0 Albumin @5 09`
C03	`04`	`X`	`SPA`	`@0 Albúmina @5 09`
C03	`05`	`X`	`FRE`	`@0 Niveau @5 10`
C03	`05`	`X`	`ENG`	`@0 Level @5 10`
C03	`05`	`X`	`SPA`	`@0 Nivel @5 10`
C03	`06`	`X`	`FRE`	`@0 Facteur prédictif @5 11`
C03	`06`	`X`	`ENG`	`@0 Predictive factor @5 11`
C03	`06`	`X`	`SPA`	`@0 Factor predictivo @5 11`
C03	`07`	`X`	`FRE`	`@0 Long terme @5 12`
C03	`07`	`X`	`ENG`	`@0 Long term @5 12`
C03	`07`	`X`	`SPA`	`@0 Largo plazo @5 12`
C03	`08`	`X`	`FRE`	`@0 Pronostic @5 13`
C03	`08`	`X`	`ENG`	`@0 Prognosis @5 13`
C03	`08`	`X`	`SPA`	`@0 Pronóstico @5 13`
C03	`09`	`X`	`FRE`	`@0 Homme @5 14`
C03	`09`	`X`	`ENG`	`@0 Human @5 14`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 14`
C03	`10`	`X`	`FRE`	`@0 Malade @5 15`
C03	`10`	`X`	`ENG`	`@0 Patient @5 15`
C03	`10`	`X`	`SPA`	`@0 Enfermo @5 15`
C03	`11`	`X`	`FRE`	`@0 Aigu @5 16`
C03	`11`	`X`	`ENG`	`@0 Acute @5 16`
C03	`11`	`X`	`SPA`	`@0 Agudo @5 16`
C03	`12`	`X`	`FRE`	`@0 France @2 NG @5 17`
C03	`12`	`X`	`ENG`	`@0 France @2 NG @5 17`
C03	`12`	`X`	`SPA`	`@0 Francia @2 NG @5 17`
C03	`13`	`X`	`FRE`	`@0 Appareil circulatoire @5 18`
C03	`13`	`X`	`ENG`	`@0 Circulatory system @5 18`
C03	`13`	`X`	`SPA`	`@0 Aparato circulatorio @5 18`
C03	`14`	`X`	`FRE`	`@0 Cardiologie @5 19`
C03	`14`	`X`	`ENG`	`@0 Cardiology @5 19`
C03	`14`	`X`	`SPA`	`@0 Cardiología @5 19`
C07	`01`	`X`	`FRE`	`@0 Europe @2 NG`
C07	`01`	`X`	`ENG`	`@0 Europe @2 NG`
C07	`01`	`X`	`SPA`	`@0 Europa @2 NG`
C07	`02`	`X`	`FRE`	`@0 Cardiopathie coronaire @5 37`
C07	`02`	`X`	`ENG`	`@0 Coronary heart disease @5 37`
C07	`02`	`X`	`SPA`	`@0 Cardiopatía coronaria @5 37`
C07	`03`	`X`	`FRE`	`@0 Pathologie du myocarde @5 38`
C07	`03`	`X`	`ENG`	`@0 Myocardial disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Miocardio patología @5 38`
N21				`@1 144`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000195

Links to Exploration step

Pascal:10-0215806

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study</title>
<author><name sortKey="Van Belle, Eric" sort="Van Belle, Eric" uniqKey="Van Belle E" first="Eric" last="Van Belle">Eric Van Belle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hopital Cardiologique and EA2693</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Dallongeville, Jean" sort="Dallongeville, Jean" uniqKey="Dallongeville J" first="Jean" last="Dallongeville">Jean Dallongeville</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut Pasteur and INSERM U744</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Vicaut, Eric" sort="Vicaut, Eric" uniqKey="Vicaut E" first="Eric" last="Vicaut">Eric Vicaut</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hopital F. VIDAL</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Degrandsart, Alexia" sort="Degrandsart, Alexia" uniqKey="Degrandsart A" first="Alexia" last="Degrandsart">Alexia Degrandsart</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratoires PFIZER</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Baulac, Cathrine" sort="Baulac, Cathrine" uniqKey="Baulac C" first="Cathrine" last="Baulac">Cathrine Baulac</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratoires PFIZER</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Cardiologie, Pitié-Salpétrière University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0215806</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0215806 INIST</idno>
<idno type="RBID">Pascal:10-0215806</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000195</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000347</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study</title>
<author><name sortKey="Van Belle, Eric" sort="Van Belle, Eric" uniqKey="Van Belle E" first="Eric" last="Van Belle">Eric Van Belle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hopital Cardiologique and EA2693</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Dallongeville, Jean" sort="Dallongeville, Jean" uniqKey="Dallongeville J" first="Jean" last="Dallongeville">Jean Dallongeville</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut Pasteur and INSERM U744</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Vicaut, Eric" sort="Vicaut, Eric" uniqKey="Vicaut E" first="Eric" last="Vicaut">Eric Vicaut</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hopital F. VIDAL</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Degrandsart, Alexia" sort="Degrandsart, Alexia" uniqKey="Degrandsart A" first="Alexia" last="Degrandsart">Alexia Degrandsart</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratoires PFIZER</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Baulac, Cathrine" sort="Baulac, Cathrine" uniqKey="Baulac C" first="Cathrine" last="Baulac">Cathrine Baulac</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratoires PFIZER</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Cardiologie, Pitié-Salpétrière University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The American heart journal</title>
<title level="j" type="abbreviated">Am. heart j.</title>
<idno type="ISSN">0002-8703</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The American heart journal</title>
<title level="j" type="abbreviated">Am. heart j.</title>
<idno type="ISSN">0002-8703</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term>
<term>Albumin</term>
<term>Cardiology</term>
<term>Cardiovascular disease</term>
<term>Circulatory system</term>
<term>France</term>
<term>Human</term>
<term>Ischemia</term>
<term>Level</term>
<term>Long term</term>
<term>Myocardial infarction</term>
<term>Patient</term>
<term>Predictive factor</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ischémie</term>
<term>Infarctus du myocarde</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Albumine</term>
<term>Niveau</term>
<term>Facteur prédictif</term>
<term>Long terme</term>
<term>Pronostic</term>
<term>Homme</term>
<term>Malade</term>
<term>Aigu</term>
<term>France</term>
<term>Appareil circulatoire</term>
<term>Cardiologie</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background Little is known about the capacity of ischemia-modified albumin (IMA) plasma concentration to predict long-term cardiac outcome in patients with established acute myocardial infarction (AMI). Because IMA is a marker of ischemia rather than myocardial cell damage, we hypothesized that IMA plasma levels could provide additional prognostic value to classic clinical and biological risk markers in patients with AMI. Therefore, we investigated the predictive value of plasma IMA in patients with AMI enrolled in the French Nationwide OPERA study. Methods Plasma concentrations of IMA and other cardiac biomarkers (troponin, C-reactive protein, B-type natriuretic peptide) were measured within 24 hours of hospital admission in 471 patients hospitalized with an AMI (defined using European Society of Cardiology/American College of Cardiology criteria). Patients' characteristics, cardiovascular risk factors and treatments, and clinical outcomes were recorded. Univariate and multivariable predictors of cardiac outcome in-hospital and at 1 year were identified. Results The primary composite end point (death, resuscitated cardiac arrest, recurrent myocardial infarction or ischemia, heart failure, stroke) occurred in 75 (15.6%) patients in-hospital and in 144 (30.6%) at 1 year: 40% of patients in the highest IMA quartile (>104 IU/mL) reached the end point compared with 20% in the lowest (<83 IU/mL) by 1 year. Multivariable logistic regression analysis identified 4 independent predictors of composite end point at 1 year: plasma concentrations of IMA (P = .01), brain natriuretic peptide (P = .001), heart failure (P = .005), and age (P = .003). Conclusions In patients with AMI, IMA measured within 24 hours is a strong and independent predictor of cardiac outcome at 1 year and may help identify those requiring more aggressive medical management.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-8703</s0>
</fA01>
<fA02 i1="01"><s0>AHJOA2</s0>
</fA02>
<fA03 i2="1"><s0>Am. heart j.</s0>
</fA03>
<fA05><s2>159</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VAN BELLE (Eric)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DALLONGEVILLE (Jean)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VICAUT (Eric)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DEGRANDSART (Alexia)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BAULAC (Cathrine)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MONTALESCOT (Gilles)</s1>
</fA11>
<fA14 i1="01"><s1>Hopital Cardiologique and EA2693</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institut Pasteur and INSERM U744</s1>
<s2>Lille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Hopital F. VIDAL</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Laboratoires PFIZER</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Institut de Cardiologie, Pitié-Salpétrière University Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>OPERA Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>570-576</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2057</s2>
<s5>354000182014920090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0215806</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The American heart journal</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background Little is known about the capacity of ischemia-modified albumin (IMA) plasma concentration to predict long-term cardiac outcome in patients with established acute myocardial infarction (AMI). Because IMA is a marker of ischemia rather than myocardial cell damage, we hypothesized that IMA plasma levels could provide additional prognostic value to classic clinical and biological risk markers in patients with AMI. Therefore, we investigated the predictive value of plasma IMA in patients with AMI enrolled in the French Nationwide OPERA study. Methods Plasma concentrations of IMA and other cardiac biomarkers (troponin, C-reactive protein, B-type natriuretic peptide) were measured within 24 hours of hospital admission in 471 patients hospitalized with an AMI (defined using European Society of Cardiology/American College of Cardiology criteria). Patients' characteristics, cardiovascular risk factors and treatments, and clinical outcomes were recorded. Univariate and multivariable predictors of cardiac outcome in-hospital and at 1 year were identified. Results The primary composite end point (death, resuscitated cardiac arrest, recurrent myocardial infarction or ischemia, heart failure, stroke) occurred in 75 (15.6%) patients in-hospital and in 144 (30.6%) at 1 year: 40% of patients in the highest IMA quartile (>104 IU/mL) reached the end point compared with 20% in the lowest (<83 IU/mL) by 1 year. Multivariable logistic regression analysis identified 4 independent predictors of composite end point at 1 year: plasma concentrations of IMA (P = .01), brain natriuretic peptide (P = .001), heart failure (P = .005), and age (P = .003). Conclusions In patients with AMI, IMA measured within 24 hours is a strong and independent predictor of cardiac outcome at 1 year and may help identify those requiring more aggressive medical management.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12A03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12A05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Ischémie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Ischemia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Isquemia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Infarctus du myocarde</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Myocardial infarction</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Infarto miocardio</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Albumine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Albumin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Albúmina</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Niveau</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Level</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Nivel</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Facteur prédictif</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Predictive factor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Factor predictivo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Long terme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Long term</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Malade</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Patient</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Enfermo</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Aigu</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Acute</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Agudo</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>France</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>France</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Francia</s0>
<s2>NG</s2>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Appareil circulatoire</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Circulatory system</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Aparato circulatorio</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Cardiologie</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Cardiology</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Cardiología</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cardiopathie coronaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronary heart disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cardiopatía coronaria</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du myocarde</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Myocardial disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Miocardio patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>144</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000347 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000347 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0215806
   |texte=   Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study

Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri